Genetic Variability and Ethnicity in Cancer Treatment Outcome: Challenges and Opportunities
Presented by AACR-Minorities in Cancer Research (MICR)
Monday, April 16, 2007
10:00 a.m. -12:00 p.m.
Room 501 A-C, Los Angeles Convention Center
Description:
Inter-individual genetic variability and ethnicity are increasingly being shown to be important co-determinants, not only of risk, but also of patient response to cancer therapy and may play a role in the differences observed between patients in the nature and level of treatment-associated normal tissue toxicity. These inherited variations occur in genes, such as, those that encode direct drug targets, or proteins involved in the transport, metabolism, and disposition of anticancer drugs. The genetic variability could also affect genes involved in cellular pathways that mediate response to therapy-induced biological perturbations, such as, DNA damage response, DNA repair, apoptosis and survival. Notable examples are correlations between polymorphisms in drug metabolizing genes and mutations in the epidermal growth factor receptor (EGFR) gene in ethnicity-based differential response to therapy with alkylating agents and EGFR inhibitors, respectively. In this forum, experts will discuss advances in the area, the clinical implications of the findings and the role that inherited genetic variability and ethnicity play in determining outcome of therapy and, whether these should influence planning and selection of cancer therapy for ethnically diverse populations.
Co-Chairpersons:
Francis Ali-Osman, Duke Univ. Comprehensive Cancer Center, Durham, NC
Judith S. Kaur, Mayo Clinic College of Medicine, Rochester, MN
Speakers:
Polymorphic Cytochrome P450 enzymes and cancer therapy
Magnus Ingelman-Sundberg, Karolinska Institutet, Stockholm, Sweden
Tamoxifen pharmacogenetics: The role of CYP2D6 in the individualization of breast cancer therapy
Matthew P. Goetz, Mayo Clinic, Rochester, NY
Glutathione S-transferases pharmacogenetics and cancer treatment outcome
Francis Ali-Osman, Duke University, Durham, NC
Prognostic factors in adult glioma
Margaret Wrensch, University of California, San Francisco, CA
Outcomes of Ovarian Cancer Treatment and Ethnicity
Veronica Schimp, Wayne State University, Detroit, MI